Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 1,290,948 | 1,167,175 | 1,097,033 | 1,249,026 | 773,689 |
| Cost of Goods | 298,451 | 211,122 | 267,723 | 200,154 | 142,953 |
| Gross Profit | 992,497 | 956,053 | 829,310 | 1,048,872 | 630,736 |
| Operating Expenses | 761,507 | 687,539 | 698,315 | 681,044 | 647,888 |
| Operating Income | 231,441 | 268,636 | 131,718 | 367,982 | -16,199 |
| Interest Expense | 82,051 | 69,286 | 88,464 | 44,398 | 61,456 |
| Other Income | 28,416 | 22,303 | 84,606 | -84,615 | 36,346 |
| Pre-tax Income | 177,806 | 221,653 | 127,860 | 238,969 | -41,309 |
| Income Tax | 13,312 | 15,662 | -25,282 | -12,115 | 30,919 |
| Net Income Continuous | 164,494 | 205,991 | 153,142 | 251,084 | -72,228 |
| Net Income | $164,494 | $205,991 | $153,142 | $251,084 | $-72,228 |
| EPS Basic Total Ops | 1.23 | 1.55 | 1.17 | 1.91 | -0.55 |
| EPS Basic Continuous Ops | 1.23 | 1.55 | 1.18 | 1.91 | -0.55 |
| EPS Diluted Total Ops | 1.21 | 1.51 | 1.18 | 1.84 | -0.55 |
| EPS Diluted Continuous Ops | 1.19 | 1.49 | 1.20 | 1.83 | -0.55 |
| EPS Diluted Before Non-Recurring Items | 1.21 | 1.51 | 0.82 | 1.84 | -0.52 |
| EBITDA(a) | $245,340 | $282,189 | $145,224 | $381,785 | $-2,255 |